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The vast majority of anti-infective therapeutics on the market or in development are small molecules; however, there is now a
nascent pipeline of biological agents in development. Until recently, phage display technologies were used mainly to produce
monoclonal antibodies (MAbs) targeted against cancer or inflammatory disease targets. Patent disputes impeded broad use of
these methods and contributed to the dearth of candidates in the clinic during the 1990s. Today, however, phage display is recog-
nized as a powerful tool for selecting novel peptides and antibodies that can bind to a wide range of antigens, ranging fromwhole
cells to proteins and lipid targets. In this review, we highlight research that exploits phage display technology as a means of dis-
covering novel therapeutics against infectious diseases, with a focus on antimicrobial peptides and antibodies in clinical or pre-
clinical development. We discuss the different strategies andmethods used to derive, select, and develop anti-infectives from
phage display libraries and then highlight case studies of drug candidates in the process of development and commercialization.
Advances in screening, manufacturing, and humanization technologies nowmean that phage display canmake a significant con-
tribution in the fight against clinically important pathogens.
Infectious diseases continue to be one of the leading causes ofhuman mortality and disability worldwide despite the increas-
ing availability of vaccines. In today’s interconnected world, infec-
tious diseases are able to spread rapidly and globally and also ap-
pear to be emerging more frequently (50). For example, new
infectious diseases have been identified at the rate of more than
one per year from the 1970s to the 1990s (120), and more have
recently emerged, with some lethal ones, such as severe acute re-
spiratory syndrome (SARS) and avian influenza, triggering major
international concern (74, 77, 116). Moreover, in 2001, the an-
thrax letter incidents highlighted the potential threat posed by the
malicious release of biological threat agents (8, 68). Today, gains
being made in many areas of infectious disease control are also
being seriously jeopardized by the spread of antimicrobial re-
sistance, with drug resistance now being a concern for many
pathogens, including methicillin-resistant Staphylococcus au-
reus (MRSA), vancomycin-resistant Enterococcus faecium (VRE),
carbapenem-resistant Klebsiella pneumoniae (NDM-1), and mul-
tidrug-resistant (MDR) Pseudomonas aeruginosa. A public health
crisis is looming, as this development of “superbugs” is coupled
with a weak pipeline of new antimicrobials reaching the market-
place, leading to the World Health Organization declaring anti-
microbial resistance to be one of the greatest threats to human
health (153).
The first bacterial genome, sequenced in 1995, led to the pros-
pect of hundreds of new genes to explore as targets, with the po-
tential advantage of being able to directly screen for therapeutic
candidates against targets identified from the genome. However,
despite the wealth of genomic data available for many pathogens,
target-based screening has been significantly less successful than
expected in finding novel acting anti-infectives (100, 107). In-
stead, most of the antimicrobials reaching the marketplace in re-
cent years have been derivative or expanded-spectrum drugs, with
very few novel anti-infectives being discovered (15, 16, 27, 28).
The shortage of new antibiotics is also exacerbated by the exit of
many pharmaceutical companies from the field despite an unmet
need for such compounds (7).
Broad-spectrum antibiotics have, until recently, been the
mainstay of antibiotic therapy. Their commercial success has lim-
ited the interest in developing pathogen-specific drugs, as exem-
plified by pathogen-specific antibodies and other biopharmaceu-
ticals. However, the increasing threat of drug-resistant bacteria
has forced a rethink on the best strategies for treating them, in-
creasing the awareness of pathogen-specific therapies. Such strat-
egies include the screening of large combinatorial chemical librar-
ies, natural products, and biologics for their ability to inhibit the
growth of specific pathogens in whole-cell assays. Compared to
small-molecule anti-infective discovery, biopharmaceuticals still
occupy a relatively new clinical development and commercial
niche. The emergence of new recombinant technologies, such as
phage display, for the discovery of monoclonal antibodies (MAbs)
and peptides has provided significant opportunities for the devel-
opment of more specific antimicrobials.
Since its invention in 1985 (128), phage display has been suc-
cessfully applied to many different areas of research, including
immunology, cancer research, drug discovery, epitope mapping,
protein-protein interactions, plant sciences, and infectious dis-
eases, targeting a broad cross-section of protein families. It has
also been used to identify small peptide ligands and antibodies
inhibiting the function of targeted receptors for a wide range of
applications. Since the 1990s, phage display has shown great po-
tential in the discovery of new therapeutics (26, 42). Some pep-
tides and MAbs derived from phage display are currently in clin-
ical or preclinical trials (42, 113). Phage display is now playing a
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significant role for the discovery of peptides and antibodies that
may serve as novel therapeutics (37, 91). In this review, we will
summarize phage display literature focused on antimicrobial
studies during the past 2 decades and review the application of the
technology in industry for developing new anti-infective drugs.
PHAGE AND PHAGE DISPLAY
M13phage.Phage display technology is based on the construction
of a polypeptide library fused to a bacteriophage coat protein.
Although T4, T7, and  phage have been used for phage display
(35, 133, 135), the most commonly used phages are M13 and fd
filamentous phage because they do not lyse infected bacteria dur-
ing their life cycle (Fig. 1). Filamentous bacteriophages consist of a
genome of circular single-stranded DNA (ssDNA) and a flexible
rod-shaped cylinder approximately 1m long and 6 nm in diam-
eter which is composed of five coat proteins. All the coat proteins
can be used for display, but pVIII and pIII are the most commonly
applied. Each M13 virion contains 2,700 copies of pVIII protein
which together compose 87% of the total virion mass. The pVIII
protein is largely -helical and rod shaped, with approximately
50% of its 50 amino acids being surface exposed, making it suit-
able for display. However, pVIII is limited to displaying short
peptide sequences due to virion package reasons. On the other
hand, pIII is an ideal option for displaying large insertions, yet the
infectivity of phages may be reduced.
Library construction. The general procedures of the phage
display experiment consist of three stages: (i) construction of a
library with peptide or antibody variants, (ii) selections based on
affinity to interested targets, and (iii) confirmation of selected
binders using biological assays and analysis. For the construction
of a library, it is important to first consider which system is most
suitable for the desired end product. There are three general
classes of phage display systems. The first is based on the natural
filamentous phage genome, the ssDNA vector. Libraries con-
structed by introducing foreign DNA inserts into the phage ge-
nome will result in the fusion gene product displayed on all the
FIG 1 Life cycle of filamentous phages. Filamentous phage binds to the F pilus of a hostE. coli cell through pIII. Then the host TolA protein starts to depolymerize
the phage coat proteins, which remain in the inner membrane for recycling. The ssDNA of the phage enters into the cytoplasm, converts into double-stranded
DNA (dsDNA), and starts replication and expression using host enzymes. ssDNA and coated pV protein dimers form the precursors of the phage. Then pV is
replaced by pVIII in the channel formed by pI, pXI, pIV, and host thioredoxin; in the meantime, mature phage particles are assembled and released.
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coat proteins. The second system entails the use of plasmid vec-
tors, also known as phagemids. A phagemid generally contains
bacterial and phage origins of replication, an antibiotic resistance
gene, and the fusion gene with a weak promoter. Third, a “hybrid
system,” which still utilizes the phage genome but which contains
both a wide-type phage gene and a fusion gene, can be employed
(167). To distinguish between these systems, Smith coined the
terms “3,” “3 3,” and “33,” respectively (129) (Fig. 2). Numbers
indicate the coat protein. For example, if the library is constructed
on pVIII, the formats are “8,” “8 8,” and “88.” In general, fusion
library DNA on phage vectors with natural phage promoters will
produce a polyvalent display on the phage surface, whereas the
phagemid vectors and hybrid phage vectors always lead to a mon-
ovalent display. In addition, because a phagemid vector contains
only a fusion gene, it needs a helper phage, which is a filamentous
phage with reduced packaging efficiency, to encapsidate into
phage particles. The valency of the display links directly to the
affinity of the binders. Monovalent display systems are more suit-
able for the identification of the strongest binders because they
allow for selection based on pure affinity, whereas polyvalent dis-
play prevents the highest-affinity clones in a selection from being
identified because it confers a high apparent affinity on weak-
binding clones. Rondot and colleagues developed Hyperphage,
which allows the use of monovalent libraries to select high-avidity
binders (115).
It is feasible to display peptides and functional antibodies with
a wide range of sizes and structures on a phage surface. However,
practically, not all peptides or proteins can be selected using phage
display. Some sequences may be toxic to the expression vector
(normally Escherichia coli), interfere with phage assembly, or be
sensitive to bacterial proteases. In addition, cysteine residues are
often rarer than expected based on predictions of randomness in
peptide libraries, a result which has been attributed to reduced
display due to the formation of inappropriate disulfide bonds.
Similar to other selection technologies, the size and quality of
libraries are crucial for the success of phage display. Random pep-
tide libraries are the most common type of phage display libraries.
Currently, methods for the production of peptide libraries are still
based on the procedure developed by Zoller and Smith (170, 171),
subsequently improved by Kunkel (63). They employed artifi-
cially synthesized oligonucleotides to introduce mutations into
the vectors, a process which can lead to library sizes from 109 to
1011; however, some libraries may contain up to 20% of wild-type
phage. By adding an amber stop codon (TAG) in the beginning of
gene III of M13 phage, Scholle and colleagues generated peptide
libraries with 100% recombinant phages (124). In 1990, McCaf-
ferty and colleagues successfully displayed antibody variable do-
mains on the surface of filamentous phage (83). Since then, single-
chain variable fragments (scFvs) or antigen-binding fragments
(Fabs) have generally been used for the construction of an anti-
body phage display library, because the complementarity-deter-
mining regions (CDRs) located at the variable domains of both
heavy chain (VH) and light chain (VL) determine the binding of
antigens. The construction of antibody libraries has been exten-
sively reviewed (94, 103, 146). The traditional approach, based on
the method established by Marks and coworkers in 1991 (76), uses
PCR assembly to randomly combine VH and VL genes into
phagemid vectors that produce human scFv repertoires. Libraries
generated using the traditional method generally contain 107
members, a size which is not sufficient enough for screening. Op-
timized and novel strategies to generate large antibody libraries
have been carried out, increasing the diversity to 1012 (23, 39, 121,
126). However, both monovalently and polyvalently displayed
scFvs and Fabs showed limitations that make them difficult for the
selections based on intrinsic affinity (103). Furthermore, the iso-
lated antibody fragments require additional cloning steps and re-
formatting in mammalian cells to generate full-length IgGs which
are suitable for therapeutic applications. Thus, libraries with func-
tional full-length antibodies displayed on phage particles may be-
come much more ideal as screening tools. Mazor and colleagues
developed an E. coli-based protein expression technology, named
E-clonal, which enables the isolation of full-length IgGs from li-
braries displayed in the periplasm of E. coli cells through fluores-
cence-activated cell sorting (FACS) (80, 81). In the E-clonal sys-
tem, a phagemid, pMAZ360-IgG, was constructed for efficient
expression of soluble intact IgGs in E. coli, and then antigen-spe-
cific IgGs were isolated by the binding to fluorescently labeled
antigen. However, FACS is not efficient enough to sort a library
with more than 109 cells. In order to solve the problem, a pre-
screening step of using phage display panning to reduce the library
size was carried out (79). A fUSE5-ZZ phage was introduced into
the system, making it possible to display full-length IgGs on phage
particles. The fUSE5-ZZ phage particles display the fragment crys-
tallizable region (Fc)-binding ZZ protein on the pIII protein. By
the infection of fUSE5-ZZ phage, soluble IgGs expressed in
pMAZ360-IgG-transformed E. coli cells were captured on the
phage particles, leading to a full-length IgG phage display library.
Combined with subsequent FACS screening, low-nanomolar-
range antibodies were isolated from the library (79). The system
flexibly applies fUSE5-ZZ phage as both a helper and a capture
phage. It significantly contributes to the development of full-
length antibody phage display libraries.
At present, although hundreds of libraries were constructed in
different research groups, the resources of commercial libraries
are very limited. The most commonly used commercial libraries
are New England BioLabs (NEB) Ph.D. phage display libraries,
which have a diversity of 109 independent peptides.
Biopanning. The phage selection procedure, also referred as
biopanning, is a highly flexible and dynamic step in a phage dis-
play experiment. It is based on affinity selection, which is a char-
acteristic aspect of the phage display technology that selects for
ligands against any target. By permitting control over selection
FIG 2 Library construction systems. Black boxes indicate the gene fragments
encoding pIII. Yellow boxes represent the foreign gene inserted into the pIII
gene. Yellow circles show the fusion proteins expressed on the N terminus of
the pIII protein.
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and screening conditions, display technologies allow the genera-
tion of antibodies/peptides against defined antigen conformations
or epitopes. In vitro methods also overcome immunological tol-
erance, allowing the selection of affinity reagents that recognize
highly conserved targets (9).
A selection cycle basically contains four stages: (i) incubation
of target molecules with a phage display library, (ii) washing off
unbound phage, (iii) elution of the bound phage, and (iv) ampli-
fication of the eluted phage. Three to four rounds of selections are
generally carried out in a biopanning experiment (Fig. 3). In ad-
dition, counterscreening selections against carrier molecules or
nonspecific targets can also be included to increase the efficiency
of biopanning. Phage particles whose displayed peptides/antibod-
ies bind the selector are captured, while all other phages are
washed away. The captured phage, generally a 108 to 107 frac-
tion of the initial library population, can then be eluted with mild
acid, alkaline, or detergent solutions without affecting phage in-
fectivity.
Although the principle of biopanning is simple, the outcome
can vary due to multiple factors, such as library complexity, nature
of the target, binding affinity and avidity, and other multiple ex-
perimental parameters. Even with an excellent selection strategy,
the experiment will fail if the desired peptide/antibody is not pres-
ent in the library. Binding affinity and avidity are other factors that
need to be taken into consideration. As described above, the va-
lency of a displayed molecule on a virion is a critical parameter in
the ranking and selection of candidates. High-affinity binders are
usually selected from a “3 3” system, while multivalent libraries
are generally used when seeking high-avidity binders. In addition,
phage libraries usually contain a population of “target-unrelated
phages” (TUPs), which can bind tightly to other materials used in
the panning procedure, such as plastic plates, streptavidin, protein
A, bovine serum albumin (BSA), etc. This can be avoided by ad-
ditional negative screening steps before the biopanning of desired
targets. Typical TUPs found in screening campaigns from phage
display libraries have been summarized by Menendez and Scott
(84).
Most protein, peptide, nucleic acid, and carbohydrate targets
can be used with phage display screening. For soluble targets, there
are many options for their immobilization. For example, they may
be coated directly on a solid surface, such as a polystyrene tube or
microplate, or they may be biotinylated and captured on a strepta-
vidin-coated plate or streptavidin-agarose beads (125). Direct
coating is easy to perform but may result in an inaccessible ligand
binding site, while the latter method involves additional steps for
the chemical modification of targets. In the case of insoluble ma-
terials, biopanning can be performed in a suspension. In most
cases, selection and screening are performed on a solid surface, so
it is important to use appropriate blocking methods to avoid the
enrichment of target-unrelated peptides or antibodies (84). His-
torically, these methods have been important for isolating pep-
tides and antibodies against known targets, such as proteins, lip-
ids, and small molecules. While standard phage display methods
use purified antigens, panning against whole cells is another op-
tion (149). In the past decade, most researchers used whole bac-
terial/mammalian cells as targets to identify receptor-specific or
cell-type-specific peptides and antibodies (5, 18, 102, 134).
The advantages of whole-cell phage display are easy to see. In
the case of when antigen is unavailable or the antigen is not stable
under immobilization conditions, whole-cell phage display pan-
ning is normally the best choice. In addition, it is also useful in the
discovery of unknown antigens. The biopanning procedure typi-
cally requires no prior knowledge of the cell surface biomarkers,
allowing for the isolation of targeting peptides for cell types for
FIG 3 Biopanning of a phage display library to select phage binding to an immobilized target.
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which little is known about the cellular profile. For whole-cell
screening, the cellular targets are identified in a two-part process.
First, peptides or antibodies are first identified by screening whole
cells against a phage display library. Second, the binding peptides
or antibodies are tested individually in functionally based screens.
In all cases, activity is confirmed in functional assays; one does not
need to either purify or identify a particular receptor in advance.
Since whole cells are used as the affinity matrix, the receptors are
likely to be in their native conformation, and a large variety of
receptors are being screened at one time. It should be noticed that
the cell surfaces would share a high degree of similarity and that
the peptides would be recognizing abundant, common receptors.
Thus, additional negative selections are necessary to avoid unex-
pected cell specificity of selected peptides. Nevertheless, it has
been reported that the specificity of phage selected in nonbiased
screens is 10- to 100-fold higher for the targeted cell type than for
other cell types (11). As such, cell-specific peptides are often more
useful for targeting certain cell types and for delivery of drugs.
With the advent of in vivo panning, it is also possible to target
specific cell types or even organs. For example, Apar and col-
leagues used in vivo screening to identify tumor vasculature-tar-
geted peptides, a process which significantly increased the effi-
ciency of an antitumor drug (3). Four years later, they successfully
separated organ-specific peptides by injecting a phage library into
the vasculature of a human volunteer (2).
PATHOGEN-TARGETED PHAGE DISPLAY
Phage display has been used widely for identification of specific
peptides and antibodies against pathogen targets. These targets are
generally subdivided into two categories: (i) molecular targets,
such as replication/cell division enzymes and host-pathogen vir-
ulence factors, and (ii) whole bacterial cells (Table 1). In compar-
ison with specific molecular targets, cell-based screening has the
advantage in that it is an assumption-free strategy with the poten-
tial to recognize cell surface structures that may not have been
considered targets using genomic-based approaches or that have
not yet been identified. Using live pathogens as the target also has
the advantage that all “druggable” targets on the cell surface are
screened simultaneously in their native physiological context,
thus allowing for the selection of potential antimicrobial activity
from the outset. Antigens on the cell surface of pathogens are
appealing targets for biologics because they provide potential
binding sites for molecules to interfere with bacterial division
(71), colonization, and virulence (111). Both strategies have been
widely applied for developing novel diagnostic tools and thera-
peutic treatments for infectious diseases. The following section
will review key achievements in this area in recent years.
Gram-positive bacteria. Staphylococcus aureus, one of the
most important human pathogens, has become a major threat to
human health, as a large percentage of S. aureus infections are
mediated by MRSA. In addition, strains resistant to vancomycin,
considered one of the “last-resort” antibiotics, have been reported
since the 1980s (150). Yacoby and colleagues used S. aureus-spe-
cific phage as a carrier to deliver high concentrations of antibiotics
to bacterial cells (160). They panned a 12-mer peptide phage dis-
play library to isolate the S. aureus-specific phages and also ex-
pressed ZZ domains, which bind tightly to immunoglobulins, on
the N terminus of the M13 major coat protein pIII. The drug was
conjugated to the N terminus of coat protein pVIII using an ester
bond. The carrying capacity of the phage was improved by linking
the phage to the aminoglycoside antibiotic neomycin (159). The
drug molecule is released from the phage surface by ester bond
hydrolysis in the presence of serum. Inhibition of bacterial growth
was significantly improved by incubating with drug-carrying
phages instead of free drug alone. Other studies have employed
phage display technology to identify small peptides that bind to S.
aureus, S. aureus membrane proteins, or S. aureus toxins (4, 55,
132, 162, 163). Those peptides showed an inhibitory effect on S.
aureus growth. However, little research has been done on MRSA
or other resistant strains to identify strain-specific peptides or an-
tibodies.
Listeria monocytogenes is a severe food-borne pathogen that
causes life-threatening listeriosis. To avoid infection by L. mono-
cytogenes, it is important to detect low levels of the pathogen in
food samples. Paoli and colleagues used phage display to identify a
scFv antibody that can bind to L. monocytogenes but not other
Listeria strains (95). Three years later, a surface plasmon reso-
nance (SPR) sensor was developed based on the scFv antibody
(90). L. monocytogenes-specific scFv-displayed phage was immo-
bilized on the sensor surface to detect L. monocytogenes at a detec-
tion limit of 2  106 CFU/ml. The mechanism of binding to and
invading host cells by L. monocytogenes is not clear, limiting the
development of appropriate preventative and therapeutic strate-
gies. Exploiting the NEB Ph.D.-12 phage-displayed peptide li-
brary, Gasanov and colleagues revealed that invasion by L. mono-
cytogenes is mediated via binding to the insulin-like growth factor
II receptor (IGFIIR) on mammalian cells (38). Additional pep-
tides that bound to L. monocytogenes were identified by panning a
9-mer peptide and 12-mer peptide phage display library (21).
Gram-negative bacteria. The bacterial cell wall is crucial for
bacterial survival. The main component of the bacterial cell
wall is peptidoglycan, a heteropolymer composed of cross-linked
N-acetylglucosamine and UDP-N-acetylmuramic acid. The syn-
thesis of the bacterial cell wall involves a series of enzymes, such as
MurA-G, transglycosylases, and transpeptidases (122, 141). Inter-
rupting any stage in the procedure can lead to failure in pepti-
doglycan synthesis and subsequent bacteria lysis, and hence, novel
antimicrobial agents targeting cell wall biosynthesis are of increas-
ing interest (127). Inhibitors of MurA were discovered by panning
against the NEB Ph.D.-12 and Ph.D.-C7C libraries using the Pseu-
domonas aeruginosa MurA enzyme, with 50% inhibitory concen-
trations (IC50s) in the 200 M range reported (87). The same
libraries were used to screen the P. aeruginosa MurC enzyme (36).
One 12-mer peptide (DHRNPNYSWLKS) and one cyclic 7-mer
peptide (CQDTPYRNC) showed similar IC50s (1.5 mM and 0.9
mM, respectively) for inhibition of MurC. However, the peptides
are not suitable for therapeutic development because of their low
permeability and susceptibility to degradation in plasma. Com-
bined with the mM range of IC50s, the peptide sequences may be
valuable only for chemical modification of new antibacterials.
Peptide inhibitors for MurE and MurF of P. aeruginosa were iden-
tified by panning on the NEB Ph.D.-12 library (96, 97). The two
peptides (NHNMHRTTQWPL and TMGFTAPRFPHY) inhib-
ited MurE and MurF activity with IC50s of 500 M and 250 M,
respectively. Furthermore, inhibitors against P. aeruginosa FtsA
and FtsZ, bacterial cell division-related proteins, were screened
out from the Ph.D.-12 and Ph.D.-C7C libraries (98, 99). In addi-
tion to panning on enzymes, P. aeruginosa whole cells have been
chosen as a target. Biosensors immobilized with phage-displayed
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TABLE 1 Phage display targets of infectious diseases
Targeta Libraryb Potential application Reference(s)
Molecular targets
TEM-1 -lactamase BLIP library Novel antimicrobial candidates 55, 163
RAP 12-mer peptide library Anti-S. aureus 162
SEB 12-mer peptide library Anti-S. aureus 132
S. aureus SdrC 12-mer peptide library Anti-S. aureus 4
P. aeruginosa MurA C7C cyclic peptide, 12-mer peptide library Anti-P. aeruginosa 87
P. aeruginosa MurC C7C cyclic peptide, 12-mer peptide library Anti-P. aeruginosa 36
P. aeruginosa MurE and MurF 12-mer peptide library Anti-P. aeruginosa 96, 97
P. aeruginosa FtsA and FtsZ C7C cyclic peptide, 12-mer peptide library Anti-P. aeruginosa 98, 99
H. pylori urease holoenzyme 25-mer peptide, 6-mer peptide library, scFv library Anti-H. pylori 53, 54, 112
H. pylori surface protein scFv library Anti-H. pylori 17
Bacterial membrane model T7 phage system, 12-mer peptide library Antibiotic design 136, 158
LPS/lipid A scFv libraries, peptide libraries Anti-Gram-negative bacterial agents 43, 44, 48, 59, 60,
78, 85, 92, 137,
169
HCV proteins scFv libraries, peptide libraries Epitope mapping, diagnostics, vaccine design 12, 13, 101, 165
HBsAg scFv library Drug delivery 152
HBcAg C7C cyclic peptide library Anti-HBV infection 51
HAV antibodies 9-mer peptide library Epitope mapping, diagnostics 66
HEV capsid protein Antibody library Anti-HEV infection 123
H5N1 HA Fab library Anti-H5N1 infection 69
H5N1 antibodies, anti-H5N1
human sera
H5N1 whole-genome-fragment libraries Epitope mapping, diagnostics, vaccine design 58
HIV-1 RT Peptide library Epitope mapping, vaccine design 34
HIV-1 V3 loop peptide scFv library Anti-HIV infection, vaccine design 138
HIV-1 vif protein 12-mer peptide library Anti-HIV infection 161
HIV-1 IZN17 peptide Cyclic 10-mer/8-mer peptide library Anti-HIV infection 151
PRRSV N protein 12-mer peptide library Detection of PRRSV 114
Malaria peptide mimics/
Plasmodium falciparum
proteins
scFv libraries Epitope mapping, therapeutic agents 22, 29, 143
Cryptosporidium parvum
glycoproteins
Fab library Treatment and diagnostics of cryptosporidiosis 24
Whole-cell targets
S. aureus 12-mer peptide library Anti-S. aureus drug design 159, 160
L. monocytogenes scFv library Diagnostics of L. monocytogenes infection 90, 95
L. monocytogenes 12-mer peptide library Discovery of novel druggable targets 38
L. monocytogenes 9-mer peptide, 12-mer peptide library Diagnostics of L. monocytogenes infection 21
P. aeruginosa 9-mer peptide, 12-mer peptide library Diagnostics of P. aeruginosa infection 20
H. pylori scFv library Diagnostics of H. pylori infection 118
P. aeruginosa, Enterobacteriaceae 10-mer peptide library Anti-Gram-negative bacterial agents 104
S. Typhimurium 8-mer peptide library Diagnostics of S. Typhimurium 131
M. arginini 20-mer peptide library Drug delivery 33
H. influenzae 15-mer peptide library Anti-H. influenzae agents 6
C. jejuni 15-mer peptide library Anti-C. jejuni agents 5
Spores of Bacillus scFv libraries, peptide libraries Detection of Bacillus species 10, 62, 140, 144,
154, 168
hCD81-transfected NIH/3T3
cell line
9-mer peptide library Anti-HCV infection 18
H9N2 virus particles 7-mer peptide library Anti-H9N2 infection 108, 109
VEEV scFv library Detection of VEEV infection 61
C. trachomatis EBs scFv library Detection of C. trachomatis 70
Rabies virus scFv library Rabies postexposure prophylaxis 166
Andes virus Cyclic C7C peptide library Therapeutic agents 45, 46
Sporozoites of E. acervulina 7-mer/C7C/12-mer peptide library Therapeutic agents 32
Sporozoites of C. parvum Fab library Treatment and diagnostics of cryptosporidiosis 24
Mosquito salivary glands 12-mer peptide library Therapeutic agents 41
a RAP, RNAIII-activating protein; SEB, staphylococcal enterotoxin B; RT, reverse transcriptase; vif, virion infectivity factor.
b BLIP, -lactamase inhibitory protein.
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peptide probes binding to P. aeruginosawhole cells were evaluated
and proved to be efficient in diagnostic assays (20).
Helicobacter pylori is a Gram-negative bacterium that causes
stomach infections. It can lead to chronic inflammation, which is
strongly linked to the development of ulcers and tumors in the
stomach. Urease, one of the important virulence factors produced
by H. pylori, has been used as a target for phage display (54).
By panning on 24-mer and 6-mer phage display peptide lib-
raries, two peptides (TFLPQPRCSALLRYLSEDGVIVPS and
YDFYWW) were shown to bind to and inhibit division of H. py-
lori. The same group selected scFv antibodies that inhibited H.
pyloriurease from a phage-displayed scFv library (53). Some of the
scFvs were displayed on the M13 phage surface, which could be
used directly for therapeutic intervention (17, 112); others were
selected from a library by biopanning on whole H. pylori cells
(118). Whole-cell phage display screening was also used to iden-
tify peptides that bound to E. coli. Pini and colleagues reported an
antimicrobial peptide (QEKIRVRLSA) with low MIC values (4 to
8 g/ml) against clinical isolates of multidrug-resistant P. aerugi-
nosa and Enterobacteriaceae (104). In addition, phage probes for
Salmonella enterica serovar Typhimurium (131) and Mycoplasma
arginini (33), peptides with antimicrobial properties for Haemo-
philus influenzae (6) and Campylobacter jejuni (5), and an anti-
body against Chlamydia trachomatis elementary bodies (EBs) (70)
have been identified.
Bacterialmembranes.Bacterial membranes are critical for cell
survival and function. As the outer leaflet of the bacterial mem-
brane is populated predominately with negatively charged phos-
pholipids, antimicrobial peptides are often comprised of cationic
and hydrophobic residues (164). One limitation in the application
of phage display to bacterial membrane screening is the paucity of
model membrane preparations available. A method of conjugat-
ing biotinylated liposomes with phospholipid contents onto mag-
netic beads coated with streptavidin has been introduced (158).
However, the primary disadvantage of this method is that the
bound phage cannot be efficiently eluted from the membranes
using mild elution conditions, such as detergents and acidic solu-
tions. Tanaka et al. employed bacterial magnetic particles, ob-
tained fromMagnetospirillummagneticum strain AMB-1, as a bac-
terial membrane model for phage biopanning (136). They used
phospholipase D (PLD) to disrupt the membrane and successfully
recovered the bound phage.
Significant effort has been devoted to targeting lipopolysaccha-
ride (LPS), the major glycolipid molecule present in the outer
membrane of Gram-negative bacteria. LPS consists of three sub-
components: (i) a highly variable O-antigen chain, (ii) a core oli-
gosaccharide, and (iii) a relatively conserved phospholipid (lipid
A). LPS is an endotoxin that binds the CD14/TLR4/MD2 receptor
complex and induces strong responses from the mammalian im-
mune system. Neutralization of LPS is one of the most promising
targets for the development of novel antimicrobial agents where
phage display could provide an approach for selection of antibod-
ies and peptides specific for LPS. Several antibodies (43, 48, 85)
and peptides (44, 59, 60, 78, 92, 169) against LPS from different
bacteria strains have been identified. Furthermore, purified lipid
A can also be used as a target for phage display screening (137).
Spores. Spores from microbes such asBacillus spp. can tolerate
extreme environmental conditions and still remain viable. High-
affinity scFv antibodies (168) and peptides (62, 140) against native
spores of Bacillus spp. were isolated from phage display libraries.
These species included Bacillus anthracis, Bacillus cereus, Bacillus
subtilis, Bacillus globigii, and Bacillus amyloliquefaciens. In addi-
tion, other research was conducted on B. anthracis, a potential
bioweapon. The latter study reported several B. anthracis-specific
peptides (10, 154) and developed biosensors for detecting the
spores of B. anthracis (144).
Viruses. Several groups worked on epitope mapping and seek-
ing specific antibodies of hepatitis C virus (HCV). Human anti-
body Fab fragments against HCV NS3 or E2 protein were isolated
from phage display libraries by an Italian research group (14, 105).
Some of the Fabs against the E2 protein showed nanomolar-range
affinity. These Fabs were then converted into full-length IgGs in a
CHO cell expression system, which successfully increased the af-
finity to E2 protein by about 100-fold (12). The same group also
performed B-cell epitope mapping of the HCV E2 protein and
identified a major epitope with strong neutralization-of-binding
(NOB) activity (13). Pereboeva and colleagues established phage
display libraries by randomly expressing fragments of HCV NS3
and NS4 and then identified the antigenic regions of those pro-
teins (101). Zhang et al. also used phage display for the epitope
mapping of the HCV E2 protein and identified two epitopes in-
volved in the HCV neutralization process (165). In addition to
epitope mapping, neutralization peptides for HCV were identi-
fied. Human CD81 (hCD81) is considered a receptor for HCV. Its
antagonist peptide, SPQYWTGPA, was found by panning on
whole hCD81-expressing NIH/3T3 cells (18). Phage display was
also used to look for high-affinity antibodies and peptides against
hepatitis B virus surface antigen (HBsAg) (51, 152) and hepatitis A
virus (HAV) (66) and neutralizing antibodies against hepatitis E
virus (HEV) capsid protein (123).
Influenza viruses are known to undergo facile antigenic drift
each year, and novel methods are needed to diagnose emergent
phenotypes in both seasonal and pandemic influenza. Lim et al.
identified H5N1 influenza hemagglutinin (HA)-specific antibod-
ies that can neutralize the H5N1 virus (69). Shortly thereafter,
Khurana and colleagues constructed H5N1 gene-fragmented
phage display libraries and used them to analyze MAbs and serum
samples collected from H5N1-infected individuals. Epitope map-
ping data derived from this study may contribute to vaccine de-
sign and diagnosis of H5N1 infection (58). In addition to influ-
enza H5N1, an antiviral peptide against influenza H9N2 was also
identified (108, 109).
There is a large amount of literature on epitope mapping stud-
ies using phage display-derived reagents. For example, De Berar-
dinis et al. identified the epitopes of HIV-1 that can prime cyto-
toxic T-cell responses (34). As well as epitope mapping studies,
pathogen detection is a major part of the literature. For example,
antibodies against Venezuelan equine encephalitis virus (VEEV)
(61) and peptides that recognize the N protein of porcine repro-
ductive and respiratory syndrome virus (PRRSV) (114) have been
identified. In 1996, phage display was used for improving the af-
finity of a MAb that bound specifically to the third hypervariable
loop of HIV (138). Furthermore, neutralization antibodies for
rabies virus glycoprotein (166) and peptide inhibitors for Andes
virus (46) and HIV-1 (151, 161) were identified and showed dif-
ferent mechanisms of inhibition.
Whole viruses have also been employed for phage display
screening. Hall et al. used a cyclic phage display library, panned
against purified UV-treated Sin Nombre virus (SNV), and ob-
tained peptides with highly specific binding affinity and inhibition
Minireview
September 2012 Volume 56 Number 9 aac.asm.org 4575
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
of virus infectivity; free peptide showed moderate inhibition,
whereas peptides conjugated onto multivalent nanoparticles
through a carboxyl linkage resulted in more-potent antiviral ac-
tivity (45).
Other pathogens. Phage display has made valuable contribu-
tions to research into other important human pathogens, such as
malaria (65). In 2001, a 12-mer peptide (PCQRAIFQSICN) that
inhibited Plasmodium invasion of midgut and salivary glands was
identified (41). In the affinity selection for binding to vector sali-
vary glands, the phage library was injected into the hemocoels of
female mosquitoes. After 30 min, the salivary glands were dis-
sected to elute and collect bound phages. To select phages binding
to the luminal side of the midgut epithelium, the phage library was
fed to mosquitoes. Interestingly, the same peptide was affinity
selected in both hemocoel infection and oral ingestion selection
strategies. Since then, phage display has rapidly contributed to
epitope mapping, diagnosis, therapeutics, and vaccine develop-
ment in malaria research (22, 29, 143). Da Silva et al. used whole
sporozoites of Eimeria acervulina as a target for peptide selection.
The peptides they obtained from the NEB Ph.D. library showed
high specificity and activity againstE. acerulina andEimeria tenella
sporozoites (32). Chen et al. constructed polyclonal Fab phage
display libraries against Cryptosporidium parvum (24). These
strategies may aid in the development of an effective immunother-
apy by targeting antigens that are involved in host-parasite inter-
actions and in the attachment and invasion of pathogens with host
cells.
DRUG DISCOVERY APPLICATIONS
The sections above detail the numerous discovery activities and
technical advances in the applications of phage display to anti-
infective research. Of equal importance and interest is the fate of
those antibodies and peptides identified by phage display screen-
ing that have progressed to clinical or preclinical development as
potential therapeutic drugs. In the following section, we highlight
some of the key commercial players in this arena and selected
“pathfinder” clinical candidates for infectious diseases (Table 2).
MedImmune (AstraZeneca). MedImmune is a pioneer of an-
tibody therapy which expanded through key acquisitions of U.S.
Bioscience in 1999 and Aviron in 2002, the integration with Cam-
bridge Antibody Technology (CAT), and subsequent strategic
alignment with its new parent company, AstraZeneca, in 2007.
Respiratory syncytial virus (RSV) is a pneumovirus that is a
common cause of lower respiratory tract infection in at-risk in-
fants. The humanized MAb palivizumab (Synagis; MedImmune)
was developed for RSV prophylaxis of at-high-risk children and
has been used since 1998 in the United States and 61 other coun-
tries for the prevention of RSV infection. The MAb binds to an
epitope in the A antigenic site of the RSV F protein (157). An
affinity-optimized version of palivizumab, motavizumab, was
generated using a directed evolution approach that allowed ma-
nipulation of the binding kinetics of the MAb variants derived
from palivizumab (155). In preclinical studies, motavizumab had
enhanced activity against RSV. It bound to the RSV F protein
70-fold more than palivizumab and exhibited a 20-fold improve-
ment in neutralization of RSV infectivity (155). In a cotton rat
model, motavizumab reduced nasal and pulmonary RSV titers by
up to 25- and 100-fold, respectively, and inhibited viral replication
in the upper respiratory tract (155). In a phase I study, motavi-
zumab significantly reduced cultivatable RSV in nasal aspirates of
previously healthy children with no adverse side effects (64). Sub-
sequently, in a phase III noninferiority trial, motavizumab was
compared directly with palivizumab for its safety and rate of RSV
hospitalization in preterm infants and children aged less than 24
months with chronic lung disease. Given 15 mg/kg of body weight
of either palivizumab or motavizumab monthly, motavizumab
was shown to be noninferior to palivizumab, resulting in a 26%
relative reduction in RSV hospitalization (19). Motavizumab also
demonstrated a significant reduction in outpatient, medically at-
tended lower respiratory tract infections compared with palivi-
zumab (19).
The circulation half-life of palivizumab and motavizumab is 3
weeks, which is not able to cover the RSV season unless several
monthly injections are administered (156). Previous studies have
shown that the neonatal Fc receptor (FcRn) is important for the
long serum half-life of IgG (40, 56). In order to improve the half-
life of the MAbs, MedImmune engineered the human Fc region to
enhance the affinity to human FcRn through phage display (31).
Variants with up to 57-fold increases in affinity were identified in
the study, and one of the variants has been further applied for the
modification of motavizumab. The engineered antibody, named
Numax-YTE or MEDI-557, has shown an increase in affinity of
human FcRn of up to 10-fold (30, 156). Numax-YTE is currently
in a phase I trial.
Affitech A/S. Affitech is a newly formed human antibody re-
search company which combined Norway-based Affitech AS and
Denmark-based Pharmexa A/S in May 2009. The core technology
applied by Affitech A/S is using phage display to generate human
TABLE 2 Companies using phage display for discovery of antimicrobials and their lead compounds
Company Drug name Pathogen/target Type of molecule Molecular target
Developmental
stage Reference(s)
MedImmune
(AstraZeneca)
Numax-YTE
(MEDI-557)
Respiratory syncytial
virus
Humanized IgG1; optimized
version of motavizumab
Antigenic A site of
the F protein
Phase I 19, 30, 31, 64,
155, 156,
157
Affitech A/S AT005 Cancer and infectious
disease
Expanded-spectrum human
version of bavituximab
PS lipid Preclinical 110, 130
Human Genome Sciences Raxibacumab B. anthracis Recombinant IgG1 PA protein FDA review 82, 86, 89
Phylogica N/Aa A. baumannii Peptide Whole cells Discovery 147, 148
Phylogica/MedImmune N/A P. aeruginosa Peptide Whole cells Discovery Unpublished
data
Isogenica N/A Drug-resistant bacteria Peptide N/A Discovery 93
a N/A, not applicable.
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antibodies for novel therapeutics. Affitech has created its own an-
tibody phagemid library with a diversity of 1010 molecules which it
is using to develop a series of human antibody therapeutics.
Human antibody AT005, for the treatment of viral diseases, is
currently in preclinical research. Affitech is collaborating with
Peregrine Pharmaceuticals, a United States-based biopharmaceu-
tical company focused on MAb therapeutics, in developing
AT005. The target of AT005 is phosphatidylserine (PS), which is
one of the most abundant anionic phospholipid molecules located
inside the plasma membrane of healthy cells. When cells become
infected by viruses or in the case of solid tumors, PS becomes
surface exposed, enabling the viruses and tumors to evade im-
mune recognition. In 2005, a mouse IgG3 MAb (3G4) that bound
to the anionic phospholipids of tumors, retarding their growth in
multiple mice models of infection, was developed (110). Based on
3G4, Peregrine Pharmaceuticals developed a chimeric version,
bavituximab, containing the VH and VK domains joined to human
IgG1K constant domains (130). In August 2010 and December
2011, Peregrine Pharmaceuticals completed phase II clinical trials
of bavituximab for advanced breast cancer and hepatitis C virus
infection, respectively. Human antibody AT005 is an improved,
fully human version of bavituximab. Once accepted for develop-
ment by Peregrine, Affitech will receive clinical development
milestone fees and eventual royalties on sales on these expanded-
spectrum anti-PS antibody products. However, the status of this
antibody is not disclosed on the Affitech website.
Human Genome Sciences (HGS). HGS is a United States-
based pioneer biopharmaceutical company which was founded in
1992. The company is very active in developing protein and anti-
body therapeutics and owns the first human MAb drug for lupus,
belimumab (Benlysta), approved in 2011 by the U.S. Food and
Drug Administration (FDA).
Raxibacumab is a human MAb discovered and developed by
HGS as a countermeasure for the treatment of inhalation anthrax.
It was isolated from a phage display library (licensed by HGS from
CAT) by affinity selection against the B. anthracis recombinant
protective antigen (PA) protein (82). The isolated antibody was
further processed to contain a human IgG1 with a  light chain
and one N-linked glycosylation site per heavy chain (82). Anthrax
is caused by the infection of the spore-forming bacterium B. an-
thracis. As the bacteria can multiply in the host’s lungs and pro-
duce toxins prior to the onset of symptoms, inhalation anthrax is
one of the most fatal forms of infection and, hence, represents one
of the greatest threats in biological warfare. The anthrax toxin,
produced by actively dividing cells, is a tripartite toxin containing
a PA protein, lethal factor (LF), and edema factor (EF). The PA
protein is a key facilitator in the progression of anthrax infection.
It enhances the binding of LF and EF to the anthrax toxin receptor
(ATR) on the mammalian cell surface and promotes LF and EF
entering the cells. These toxins inhibit normal immune function,
interfere with signal transduction pathways, and ultimately cause
cell death. Raxibacumab specifically binds to PA and prevents its
binding to ATR with an IC50 of 503 pM (86).
In 2009, two animal efficacy studies demonstrated the life-sav-
ing potential of raxibacumab as a prophylactic and postexposure
therapeutic agent when administered as a single dose (89). In pro-
phylactic studies, raxibacumab provided complete protection in
rabbits and up to 90% survival at day 28 in monkeys at a dosage of
40 mg/kg (86). In postexposure studies, raxibacumab at 40 mg/kg
was also protective against the lethal effects of anthrax, with the
survival rate significantly higher in rabbits receiving raxibacumab
(44%) than in those receiving a placebo (0%). In a monkey ther-
apeutic model, the survival rate increased to 64% during the lethal
stage of the challenge compared with the placebo (0%) (82, 86). In
105 healthy volunteers, a randomized, single-blind, placebo-con-
trolled, dose escalation study was conducted to evaluate the safety,
pharmacokinetics, and biological activity of raxibacumab. Raxi-
bacumab was safe, well tolerated, and bioavailable after a single
intramuscular (IM) or intravenous (IV) dose (86).
Raxibacumab received fast-track designation from the FDA,
which enabled expedited development of the drug as a prophylac-
tic countermeasure to natural and artificial infection with B. an-
thracis. In April 2009, HGS completed 20,000 doses for the U.S.
Strategic National Stockpile, and from 2009 to 2012, HGS is de-
livering another 45,000 doses.
Phylogica and Dynamic Microbials. Phylogica is a peptide
drug discovery company based in Perth, Australia, and Oxford,
United Kingdom. The company formed in 2005. They developed
Phylomer peptide libraries, which are the main methodology they
use to identify peptide drug candidates (147). Phylogica claimed
that Phylomer libraries are the largest and most structurally di-
verse libraries of natural peptides, containing billions of distinct
peptide sequences that represent a rich source of biologically ac-
tive drug leads for a broad range of disease targets. In 2008, Phy-
logica acquired 100% outstanding shares in Dynamic Microbials,
another Australia-based biotechnology company. In the same
year, Dynamic Microbials successfully isolated peptides binding
to the whole cells of Acinetobacter baumannii and found peptides
that inhibited the growth of A. baumannii in vitro using T7 phage
display. The peptides were then patented by World Intellectual
Property Organization (WIPO) (148). In August 2010, Phylogica
initiated the collaboration with MedImmune for seeking new
treatments for the control of P. aeruginosa. In this agreement,
Phylogica is responsible for screening Phylomer libraries for new
leads against P. aeruginosa and MedImmune performs testing and
subsequent preclinical and clinical studies.
Isogenica. Isogenica is a United Kingdom-based company fo-
cused on providing protein and antibody discovery and design to
pharmaceutical and biotechnology companies. Isogenica devel-
oped an in vitro library selection system called CIS display (93).
The system can be considered an improved version of phage dis-
play. It is a DNA-based approach in which DNA fragments encod-
ing a diverse peptide library are ligated to the gene of a DNA
replication initiator protein, RepA. The word “CIS” is derived
from cis activity of the RepA protein, which refers to the exclusive
binding to its template DNA. The system allows peptides and pro-
teins to be displayed in vitro associated with their encoding DNA
templates. In 2010, Isogenica entered into an agreement with the
United Kingdom Ministry of Defense agency, the Defense Science
and Technology Laboratory (DSTL), regarding the development
of antimicrobial peptides against a broad spectrum of bacteria,
including MRSA and Clostridium difficile. Isogenica also an-
nounced a series of collaboration agreements with pharmaceutical
companies and biotechnology companies, such as Johnson &
Johnson, Phylogica, and NovaBiotics, for the development of
novel anti-infective technology platforms.
Safety, PK, and PD of therapeutic MAbs and peptides. Phar-
macokinetic (PK) and pharmacodynamic (PD) properties of an-
tibody and peptide drugs are more complicated than those of
small molecules (molecular weight  1,000), especially for anti-
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bodies because of their massive size. Comprehensive reviews ad-
dressing PK and PD properties of protein-based drugs have been
published previously (75, 88, 145). The administration of MAb
drugs is generally IV, IM, or subcutaneous (SC). Oral administra-
tion has not been successfully developed, as antibodies can hardly
diffuse through the gastrointestinal epithelium and are easily de-
graded in the gastrointestinal tract. The distribution of antibody
drugs depends on several factors, including the rates of distribu-
tion, binding, and elimination in different tissues. Furthermore,
antibody drug elimination occurs mainly via secretion into bile
(IgA) or intracellular catabolism (IgG). Filtration through the re-
nal system is not important for the elimination of antibody drugs
due to their large size. Anti-infective MAbs introduced in this
section are mostly in the discovery or preclinical stage. Raxi-
bacumab is the only MAb that is currently under FDA review.
Nevertheless, more than 130 proteins or peptides have been ap-
proved as therapeutic drugs by the FDA, including more than 20
MAbs and 50 peptides that are therapeutics for different human
diseases (1, 67). The number keeps increasing and will hopefully
double within the following several years.
PHAGE DISPLAY AND OTHER TECHNOLOGIES FOR DRUG
DEVELOPMENT
Like other affinity selection technologies, phage display also has its
problems. For novel antimicrobial agent discovery, including
peptides and MAbs, phage display showed a high probability of
identifying peptides and MAbs with relatively low binding affinity,
and a lot of them lack key attributes, such as antimicrobial activity,
or need further modification to improve the activity. For example,
reconstruction of scFvs and Fabs in mammalian cells is necessary
so that full-length antibodies can be achieved. In addition, cat-
ionic peptides with antimicrobial properties always show nonspe-
cific binding and a lot of toxicity to mammalian cells (37, 42, 47),
which limits the application of phage displays to screen peptide
libraries.
In recent years, alternative display technologies, such as ap-
tamers, ribosome display, and mRNA display, are engaged in dis-
covery of novel anti-infectives; however, pros and cons are obvi-
ous. For example, aptamer, a single-stranded oligonucleotide that
specifically binds to molecular targets such as proteins, benefits
from its smaller size, is easier to modify, and has larger-scale syn-
thesis than antibody therapeutics (57, 117). Nevertheless, short
half-life and target- and application-dependent optimization are
the main drawbacks of it. Moreover, the technologies for generat-
ing aptamers, including SELEX (systematic evolution of ligands
by exponential enrichment), are largely protected by intellectual
property (IP) portfolios (57, 117). Both ribosome display and
mRNA display are considered representatives of the next-genera-
tion display system. The main advantage of these two technologies
is that the cell-free system bypasses the cell culture procedure and
makes the screening progress faster and more efficient than cell-
based systems (49, 106). In these two systems, protein libraries are
displayed in vitro in association with their encoding mRNA. After
the affinity selection, mRNA encoding the bound protein is easily
achieved and amplified by PCR for next-round screening. The
cell-free property also offers benefits in generating and screening
large libraries (1012 to 1014). Despite the advantages, the two tech-
nologies both employed mRNA for encoding libraries, which may
degrade quickly. Cell-free systems face downstream processes
similar to those of phage display: production of the selected pro-
teins. Although cell-free protein synthesis is an option, it is not
sufficient for large-scale production at present.
Compared to in vitro technologies, traditional hybridoma is
much more reliable to generate functional MAbs regardless of its
expensive cost and long-term process. However, the inherent im-
munogenicity of rodent antibodies restricts the therapeutic po-
tency of those MAbs. Thus, transgenic mice that express antibod-
ies with human CDRs have been developed (73). The technology
has been employed by several biotechnology companies, such as
Amgen/Abgenix, Medarex, and Johnson & Johnson, to develop
human MAb drugs and has exhibited potential to create very-
high-affinity MAbs (72). Recently, a novel technology identifying
MAbs from immortalized human B cells was established (139).
The European groups successfully isolated anti-SARS coronavirus
MAbs by immortalizing memory B cells from a postconvalescent
patient. The method definitely provides researchers with an excit-
ing approach for generating therapeutic human MAbs (58, 142).
POTENCY AND DEVELOPMENT TIMESCALES AND SUCCESS
For almost all indications, a drug must bind to its molecular target
with a reasonable degree of affinity to be effective. Approximately
60% of small-molecule drug discovery projects fail in hit-to-lead
because the biological target was found to not be “druggable” or
the molecules did not possess the required potency for the target
(25). Phage display may provide advantages in facilitating screen-
ing of diverse molecular targets to obtain high-potency (e.g., nM
affinity) candidates suitable for therapeutic development within a
much faster timescale than that achievable for small molecules
(52). In the small-molecule or medicinal chemistry space, initial
“hit” molecules from library screening are normally found with
target affinities or 50% effective concentrations (EC50s)/IC50s in
the 1 to 5 M range. Many cycles of structure activity design,
synthesis, and testing are required to derive molecules with nM
potency, a task that often takes more than a year and a large team
of dedicated synthetic and medicinal chemists. Indeed, for many
targets, requisite potency is simply not achievable with small mol-
ecules, which, by definition, possess a limited surface area of con-
tact with the target. In contrast, the power of recombinant tech-
niques can drive selection/affinity maturation cycles using phage
display to derive potent “lead” molecules within weeks to months.
As a word of caution, it should be noted that high affinities/
potencies are not routinely retrieved from commercially available
naive libraries (119). Target knowledge and expertise in molecular
biology techniques are still required to design a specific peptide
library or an immune antibody library that leads to potent, selec-
tive hits. In addition, some peptides/MAbs may function only
when the peptide is an integral part of the phage coat protein or
other avidity scaffold and not when isolated free in solution (104,
129).
It is still true that the vast majority of antibiotics and antivirals
on the market or in development are small molecules; however,
there is now a nascent pipeline of biological drug candidates in
development. Until recently, phage display technologies were
used to produce MAbs for application mainly in the areas of can-
cer and inflammatory disease. Patent disputes impeded broad use
of key methods and contributed to the dearth of MAb candidates
in the clinic during the 1990s. Screening of naïve and immunized
libraries using phage display potentially allows one to develop
fully human MAbs against infectious agents and has potential to
impact our ability to treat infections refractive to current drug
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regimes. It is also important to consider the attrition rate of bio-
logical versus small molecules in the clinical development phase.
The rates of successful transition from phase I (proof of safety) to
phase II (proof of efficacy) for all therapeutic MAbs derived from
transgenic mouse and from phage display technologies are 87%
and 94%, respectively. From phase II to FDA approval, the success
rates are 52% and 37%, respectively (91). Hence, phage display-
derived MAbs are benchmarking at a 35% rate of successful pas-
sage from phase I to launch, compared to an industry-wide aver-
age of 12% for a small-molecule drug candidate. Given the paucity
of new antimicrobial and antiviral agents in clinical or preclinical
development, we believe it is imperative to consider alternative
approaches to classical small-molecule discovery.
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